Literature DB >> 23221186

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Dawn M Sievert1, Philip Ricks, Jonathan R Edwards, Amy Schneider, Jean Patel, Arjun Srinivasan, Alex Kallen, Brandi Limbago, Scott Fridkin.   

Abstract

OBJECTIVE: To describe antimicrobial resistance patterns for healthcare-associated infections (HAIs) reported to the National Healthcare Safety Network (NHSN) during 2009-2010.
METHODS: Central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated pneumonia, and surgical site infections were included. Pooled mean proportions of isolates interpreted as resistant (or, in some cases, nonsusceptible) to selected antimicrobial agents were calculated by type of HAI and compared to historical data.
RESULTS: Overall, 2,039 hospitals reported 1 or more HAIs; 1,749 (86%) were general acute care hospitals, and 1,143 (56%) had fewer than 200 beds. There were 69,475 HAIs and 81,139 pathogens reported. Eight pathogen groups accounted for about 80% of reported pathogens: Staphylococcus aureus (16%), Enterococcus spp. (14%), Escherichia coli (12%), coagulase-negative staphylococci (11%), Candida spp. (9%), Klebsiella pneumoniae (and Klebsiella oxytoca; 8%), Pseudomonas aeruginosa (8%), and Enterobacter spp. (5%). The percentage of resistance was similar to that reported in the previous 2-year period, with a slight decrease in the percentage of S. aureus resistant to oxacillins (MRSA). Nearly 20% of pathogens reported from all HAIs were the following multidrug-resistant phenotypes: MRSA (8.5%); vancomycin-resistant Enterococcus (3%); extended-spectrum cephalosporin-resistant K. pneumoniae and K. oxytoca (2%), E. coli (2%), and Enterobacter spp. (2%); and carbapenem-resistant P. aeruginosa (2%), K. pneumoniae/oxytoca (<1%), E. coli (<1%), and Enterobacter spp. (<1%). Among facilities reporting HAIs with 1 of the above gram-negative bacteria, 20%-40% reported at least 1 with the resistant phenotype.
CONCLUSION: While the proportion of resistant isolates did not substantially change from that in the previous 2 years, multidrug-resistant gram-negative phenotypes were reported from a moderate proportion of facilities.

Entities:  

Mesh:

Year:  2012        PMID: 23221186     DOI: 10.1086/668770

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  505 in total

1.  Next-Generation Sequencing and Comparative Analysis of Sequential Outbreaks Caused by Multidrug-Resistant Acinetobacter baumannii at a Large Academic Burn Center.

Authors:  Hajime Kanamori; Christian M Parobek; David J Weber; David van Duin; William A Rutala; Bruce A Cairns; Jonathan J Juliano
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

2.  Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Authors:  Kimberly C Claeys; Evan J Zasowski; Anthony M Casapao; Abdalhamid M Lagnf; Jerod L Nagel; Cynthia T Nguyen; Jessica A Hallesy; Mathew T Compton; Keith S Kaye; Donald P Levine; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017.

Authors:  Lindsey M Weiner-Lastinger; Sheila Abner; Jonathan R Edwards; Alexander J Kallen; Maria Karlsson; Shelley S Magill; Daniel Pollock; Isaac See; Minn M Soe; Maroya S Walters; Margaret A Dudeck
Journal:  Infect Control Hosp Epidemiol       Date:  2019-11-26       Impact factor: 3.254

Review 4.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

5.  An aryl isonitrile compound with an improved physicochemical profile that is effective in two mouse models of multidrug-resistant Staphylococcus aureus infection.

Authors:  Haroon Mohammad; Kwaku Kyei-Baffour; Nader S Abutaleb; Mingji Dai; Mohamed N Seleem
Journal:  J Glob Antimicrob Resist       Date:  2019-04-30       Impact factor: 4.035

6.  Staphylococcal enterotoxin P predicts bacteremia in hospitalized patients colonized with methicillin-resistant Staphylococcus aureus.

Authors:  Michael S Calderwood; Christopher A Desjardins; George Sakoulas; Robert Nicol; Andrea Dubois; Mary L Delaney; Ken Kleinman; Lisa A Cosimi; Michael Feldgarden; Andrew B Onderdonk; Bruce W Birren; Richard Platt; Susan S Huang
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

7.  The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Rosemary Soave; Alexandra C Racanelli; Tsiporah B Shore; Koen van Besien; Stephen G Jenkins; Thomas J Walsh
Journal:  Leuk Lymphoma       Date:  2014-03-24

8.  Multiple roles for Enterococcus faecalis glycosyltransferases in biofilm-associated antibiotic resistance, cell envelope integrity, and conjugative transfer.

Authors:  Jennifer L Dale; Julian Cagnazzo; Chi Q Phan; Aaron M T Barnes; Gary M Dunny
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

9.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.

Authors:  Lindsey M Weiner; Amy K Webb; Brandi Limbago; Margaret A Dudeck; Jean Patel; Alexander J Kallen; Jonathan R Edwards; Dawn M Sievert
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

10.  In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Kirk Nelson; Debora Rubio-Aparicio; Ruslan Tsivkovski; Dongxu Sun; Maxim Totrov; Michael Dudley; Olga Lomovskaya
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.